Lucida Medical
AI-powered MRI analysis for prostate cancer detection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Lucida Medical is a UK-based health technology company that develops artificial intelligence-powered software to improve the accuracy and efficiency of cancer diagnosis. Founded in 2019 by Dr. Antony Rix and Professor Evis Sala, the company spun out of the University of Cambridge and Addenbrooke's Hospital. Dr. Rix has over 25 years of experience in AI and software, while Professor Sala is an internationally recognized expert in cancer imaging. Their shared vision was to use AI to make the detection of cancer more accurate, cost-effective, and productive.
The company's flagship product is the Prostate Intelligence (Pi) platform, a CE-marked medical device software that assists radiologists in analyzing MRI scans for prostate cancer. Pi uses machine learning and image processing to identify suspicious lesions, calculate risk scores, and generate report templates. This technology aims to help radiologists locate cancer more precisely, reduce the number of unnecessary biopsies, and decrease the rate of missed cancers. Clinical studies have indicated that Pi's performance is equivalent to that of expert radiologists. The software is designed to integrate into existing hospital workflows, saving radiologists' time and helping to address workforce shortages.
Lucida Medical operates on a B2B model, partnering with hospitals, radiology and urology clinics, and healthcare systems like the UK's National Health Service (NHS) to implement its software. The company has received funding from investors including XTX Ventures, Prostate Cancer Research, and Macmillan Cancer Support. It has also engaged in strategic collaborations with organizations like GE Healthcare and several NHS Trusts to further develop and validate its platform. While its initial focus is prostate cancer, the company is extending its platform to support active surveillance and plans to address other cancers in the future.
Keywords: AI medical imaging, prostate cancer diagnostics, MRI analysis software, radiogenomics, machine learning, radiology workflow, cancer detection, medical device software, clinical decision support, health technology, lesion detection, biopsy avoidance, oncology AI, PI-RADS, active surveillance